Mr. Pierre Labbe reports

IMV INC. TO ANNOUNCE THIRD QUARTER 2018 FINANCIAL RESULTS AND HOST EARNINGS CALL ON NOVEMBER 2, 2018

IMV Inc. will hold a conference call and webcast on Friday, Nov. 2, 2018, at 8 a.m. ET to discuss the company's third quarter financial and operational results.

The dial-in number for the conference call is 844-461-9932 (United States and Canada) or 636-812-6632 (international) with the conference ID: 5779058. Those interested can access the live audio webcast on-line. The webcast will be recorded and available on the IMV website for 30 days following the call.

About IMV Inc.

IMV, formerly Immunovaccine, is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the company's proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the reprogramming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T-cell activating immunotherapy that combines the utility of the platform with a target: survivin.

We seek Safe Harbor.